Reversal of Drug Resistance in Cancer Cells
Author Information
Author(s): Vanhoefer U, Müller M R, Hilger R A, Lindtner B, Klaassen U, Schleucher N, Rustum Y M, Seeber S
Primary Institution: Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School
Hypothesis
Can PAK-200S reverse resistance to topotecan in cancer cells expressing P-glycoprotein?
Conclusion
PAK-200S effectively reversed drug resistance to topotecan in certain cancer cells by restoring drug concentrations.
Supporting Evidence
- PAK-200S completely reversed resistance to topotecan in resistant cancer cells.
- The study showed that PAK-200S restored drug concentrations in resistant cells to levels seen in non-resistant cells.
- Exposure to PAK-200S increased DNA damage in resistant cancer cells treated with topotecan.
Takeaway
This study found that a new drug, PAK-200S, can help cancer cells that are resistant to another drug, topotecan, work better again.
Methodology
The study used cellular pharmacokinetic studies and high-performance liquid chromatography to analyze drug concentrations.
Participant Demographics
The study focused on human breast and ovarian tumor cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website